{"id":"https://openalex.org/W2802749607","doi":"https://doi.org/10.1016/j.ijpharm.2018.04.062","title":"Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment","display_name":"Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment","alternate_titles":[],"publication_year":2018,"publication_date":"2018-04-30","ids":{"openalex":"https://openalex.org/W2802749607","doi":"https://doi.org/10.1016/j.ijpharm.2018.04.062","mag":"2802749607","pmid":"https://pubmed.ncbi.nlm.nih.gov/29715532"},"language":"en","primary_location":{"id":"doi:10.1016/j.ijpharm.2018.04.062","doi":"https://doi.org/10.1016/j.ijpharm.2018.04.062","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ijpharm.2018.04.062","pdf_url":null,"source":{"id":"https://openalex.org/S131016564","display_name":"International Journal of Pharmaceutics","issn_l":"0378-5173","issn":["0378-5173","1873-3476"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Pharmaceutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2802749607"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://univ-artois.hal.science/hal-02506188","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003325901","display_name":"Maria Jo\u00e3o Ramalho","orcid":"https://orcid.org/0000-0003-2428-7520","observed_orcids":["https://orcid.org/0000-0003-2428-7520"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M.J. Ramalho","raw_affiliation_strings":["LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090653750","display_name":"Emmanuel Sevin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I44563897","display_name":"Universit\u00e9 d'Artois","ror":"https://ror.org/053x9s498","country_code":"FR","type":"education","lineage":["https://openalex.org/I44563897"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"E. Sevin","raw_affiliation_strings":["University of Artois, EA 2465, Blood-brain Barrier LABORATORY (LBHE), F-62300 Lens, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Artois, EA 2465, Blood-brain Barrier LABORATORY (LBHE), F-62300 Lens, France","institution_ids":["https://openalex.org/I44563897"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046200375","display_name":"Fabien Gosselet","orcid":"https://orcid.org/0000-0002-0481-5026","observed_orcids":["https://orcid.org/0000-0002-0481-5026"]},"institutions":[{"id":"https://openalex.org/I44563897","display_name":"Universit\u00e9 d'Artois","ror":"https://ror.org/053x9s498","country_code":"FR","type":"education","lineage":["https://openalex.org/I44563897"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F. Gosselet","raw_affiliation_strings":["University of Artois, EA 2465, Blood-brain Barrier LABORATORY (LBHE), F-62300 Lens, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Artois, EA 2465, Blood-brain Barrier LABORATORY (LBHE), F-62300 Lens, France","institution_ids":["https://openalex.org/I44563897"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042372238","display_name":"Jorge Pereira Lima","orcid":"https://orcid.org/0000-0001-7780-0901","observed_orcids":["https://orcid.org/0000-0001-7780-0901"]},"institutions":[{"id":"https://openalex.org/I182534213","display_name":"Universidade do Porto","ror":"https://ror.org/043pwc612","country_code":"PT","type":"education","lineage":["https://openalex.org/I182534213"]},{"id":"https://openalex.org/I4210158732","display_name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto","ror":"https://ror.org/04wjk1035","country_code":"PT","type":"facility","lineage":["https://openalex.org/I182534213","https://openalex.org/I4210158732"]}],"countries":["PT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Lima","raw_affiliation_strings":["Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal; Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, R. Alfredo Allen, 4200-135 Porto, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto, R. J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal","Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal","Institute of Molecular Pathology and Immunology of the University of Porto, R. J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal","Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, R. Alfredo Allen, 4200-135 Porto, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal; Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, R. Alfredo Allen, 4200-135 Porto, Portugal; Institute of Molecular Pathology and Immunology of the University of Porto, R. J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal","institution_ids":["https://openalex.org/I182534213","https://openalex.org/I4210158732"]},{"raw_affiliation_string":"Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal","institution_ids":["https://openalex.org/I182534213"]},{"raw_affiliation_string":"Institute of Molecular Pathology and Immunology of the University of Porto, R. J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal","institution_ids":["https://openalex.org/I182534213"]},{"raw_affiliation_string":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, R. Alfredo Allen, 4200-135 Porto, Portugal","institution_ids":["https://openalex.org/I182534213","https://openalex.org/I4210158732"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011524809","display_name":"Manuel A. N. Coelho","orcid":"https://orcid.org/0000-0002-7312-3429","observed_orcids":["https://orcid.org/0000-0002-7312-3429"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M.A.N. Coelho","raw_affiliation_strings":["LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022038578","display_name":"Joana A. Loureiro","orcid":"https://orcid.org/0000-0002-9841-3967","observed_orcids":["https://orcid.org/0000-0002-9841-3967"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J.A. Loureiro","raw_affiliation_strings":["LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073105398","display_name":"Maria do Carmo Pereira","orcid":"https://orcid.org/0000-0001-8505-3432","observed_orcids":["https://orcid.org/0000-0001-8505-3432"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"M.C. Pereira","raw_affiliation_strings":["LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal. Electronic address: mcsp@fe.up.pt","LEPABE \u2013 Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal. Electronic address: mcsp@fe.up.pt","institution_ids":[]},{"raw_affiliation_string":"LEPABE \u2013 Laboratory for Process Engineering, Environment, Biotechnology and Energy, R. Dr. Roberto Frias, 4200-465 Porto, Portugal","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5073105398"],"corresponding_institution_ids":[],"apc_list":{"value":4650,"currency":"USD","value_usd":4650},"apc_paid":null,"fwci":4.516,"has_fulltext":false,"cited_by_count":152,"citation_normalized_percentile":{"value":0.97059089,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"545","issue":"1-2","first_page":"84","last_page":"92"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.9079999923706055},{"id":"https://openalex.org/keywords/plga-nanoparticles","display_name":"PLGA nanoparticles","score":0.9710000157356262},{"id":"https://openalex.org/keywords/transferrin-receptor","display_name":"transferrin receptor","score":0.8370000123977661},{"id":"https://openalex.org/keywords/receptor-mediated-drug-delivery","display_name":"receptor-mediated drug delivery","score":0.8299999833106995},{"id":"https://openalex.org/keywords/targeted-drug-delivery","display_name":"targeted drug delivery","score":0.6980000138282776},{"id":"https://openalex.org/keywords/nanoparticle-uptake","display_name":"nanoparticle uptake","score":0.6209999918937683},{"id":"https://openalex.org/keywords/drug-release-profile","display_name":"drug release profile","score":0.7609999775886536},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.7329999804496765},{"id":"https://openalex.org/keywords/u87-cells","display_name":"U87 cells","score":0.7210000157356262},{"id":"https://openalex.org/keywords/brain-tumor-chemotherapy","display_name":"brain tumor chemotherapy","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.8072324991226196},{"id":"https://openalex.org/C18150654","wikidata":"https://www.wikidata.org/wiki/Q17153796","display_name":"Nanocarriers","level":3,"score":0.7727999687194824},{"id":"https://openalex.org/C32264632","wikidata":"https://www.wikidata.org/wiki/Q1134983","display_name":"Transferrin receptor","level":3,"score":0.7348144054412842},{"id":"https://openalex.org/C139770010","wikidata":"https://www.wikidata.org/wiki/Q1339807","display_name":"Internalization","level":3,"score":0.724334180355072},{"id":"https://openalex.org/C2780165375","wikidata":"https://www.wikidata.org/wiki/Q2102907","display_name":"PLGA","level":3,"score":0.6489537954330444},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.5921155214309692},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5227565765380859},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5149146318435669},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4853862524032593},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4698335826396942},{"id":"https://openalex.org/C22814914","wikidata":"https://www.wikidata.org/wiki/Q410473","display_name":"Transferrin","level":2,"score":0.4643799066543579},{"id":"https://openalex.org/C2779820397","wikidata":"https://www.wikidata.org/wiki/Q1392806","display_name":"Drug delivery","level":2,"score":0.4436682164669037},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.3918297290802002},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3913918733596802},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3906145393848419},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.30007773637771606},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2440250813961029},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2436329424381256},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.14644190669059753},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11751601099967957},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077182","descriptor_name":"Polylactic Acid-Polyglycolic Acid Copolymer","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077204","descriptor_name":"Temozolomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004337","descriptor_name":"Drug Carriers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004339","descriptor_name":"Drug Compounding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007700","descriptor_name":"Kinetics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011100","descriptor_name":"Polyglycolic Acid","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D011990","descriptor_name":"Receptors, Transferrin","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D011990","descriptor_name":"Receptors, Transferrin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D013678","descriptor_name":"Technology, Pharmaceutical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018906","descriptor_name":"Antineoplastic Agents, Alkylating","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D019344","descriptor_name":"Lactic Acid","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D036103","descriptor_name":"Nanotechnology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D053758","descriptor_name":"Nanoparticles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D065546","descriptor_name":"Drug Liberation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.ijpharm.2018.04.062","doi":"https://doi.org/10.1016/j.ijpharm.2018.04.062","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ijpharm.2018.04.062","pdf_url":null,"source":{"id":"https://openalex.org/S131016564","display_name":"International Journal of Pharmaceutics","issn_l":"0378-5173","issn":["0378-5173","1873-3476"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Pharmaceutics","raw_type":"journal-article"},{"id":"pmid:29715532","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29715532","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of pharmaceutics","raw_type":"Journal Article"},{"id":"pmh:oai:HAL:hal-02506188v1","doi":null,"is_oa":true,"landing_page_url":"https://univ-artois.hal.science/hal-02506188","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"International Journal of Pharmaceutics, 2018, 545 (1-2), pp.84-92. &#x27E8;10.1016/j.ijpharm.2018.04.062&#x27E9;","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:repositorio-aberto.up.pt:10216/115698","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/10216/115698","pdf_url":null,"source":{"id":"https://openalex.org/S4306402433","display_name":"Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"journal article"}],"best_oa_location":{"id":"pmh:oai:HAL:hal-02506188v1","doi":null,"is_oa":true,"landing_page_url":"https://univ-artois.hal.science/hal-02506188","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"International Journal of Pharmaceutics, 2018, 545 (1-2), pp.84-92. &#x27E8;10.1016/j.ijpharm.2018.04.062&#x27E9;","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320334779","display_name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","ror":"https://ror.org/00snfqn58"},{"id":"https://openalex.org/F4320335322","display_name":"European Regional Development Fund","ror":"https://ror.org/00k4n6c32"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":53,"referenced_works":["https://openalex.org/W745338504","https://openalex.org/W769841729","https://openalex.org/W1539664785","https://openalex.org/W1901198588","https://openalex.org/W1931867099","https://openalex.org/W1991300039","https://openalex.org/W1993760429","https://openalex.org/W1996184101","https://openalex.org/W2009081910","https://openalex.org/W2011005493","https://openalex.org/W2014712282","https://openalex.org/W2020217107","https://openalex.org/W2020398834","https://openalex.org/W2025183726","https://openalex.org/W2032167680","https://openalex.org/W2032965857","https://openalex.org/W2046480913","https://openalex.org/W2052578334","https://openalex.org/W2059729412","https://openalex.org/W2060147931","https://openalex.org/W2062035530","https://openalex.org/W2072780919","https://openalex.org/W2082640094","https://openalex.org/W2087032263","https://openalex.org/W2089003952","https://openalex.org/W2089773350","https://openalex.org/W2090416100","https://openalex.org/W2096287682","https://openalex.org/W2105505534","https://openalex.org/W2109689528","https://openalex.org/W2114873155","https://openalex.org/W2116606676","https://openalex.org/W2116728374","https://openalex.org/W2121396361","https://openalex.org/W2133367407","https://openalex.org/W2150737519","https://openalex.org/W2154858628","https://openalex.org/W2159821105","https://openalex.org/W2168127523","https://openalex.org/W2171413845","https://openalex.org/W2280735232","https://openalex.org/W2293134842","https://openalex.org/W2338700137","https://openalex.org/W2342050478","https://openalex.org/W2395300225","https://openalex.org/W2397459131","https://openalex.org/W2496442464","https://openalex.org/W2508896552","https://openalex.org/W2525716840","https://openalex.org/W2587902106","https://openalex.org/W2785041433","https://openalex.org/W4231936026","https://openalex.org/W4235749685"],"related_works":["https://openalex.org/W2280735232","https://openalex.org/W2922257635","https://openalex.org/W4385490199","https://openalex.org/W7156022242","https://openalex.org/W2751350201","https://openalex.org/W4415243346","https://openalex.org/W3121542443","https://openalex.org/W4412619160","https://openalex.org/W4407143093","https://openalex.org/W2535773034"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2802749607","counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":19},{"year":2024,"cited_by_count":13},{"year":2023,"cited_by_count":23},{"year":2022,"cited_by_count":26},{"year":2021,"cited_by_count":18},{"year":2020,"cited_by_count":29},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2018-05-17T00:00:00"}
